Jubilant Life Sciences is currently trading at Rs. 721.00, up by 13.45 points or 1.90% from its previous closing of Rs. 707.55 on the BSE.
The scrip opened at Rs. 710.00 and has touched a high and low of Rs. 728.00 and Rs. 704.00 respectively. So far 59078 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 765.00 on 07-Feb-2017 and a 52 week low of Rs. 287.20 on 29-Feb-2016.
Last one week high and low of the scrip stood at Rs. 728.00 and Rs. 682.80 respectively. The current market cap of the company is Rs. 11476.21 crore.
The promoters holding in the company stood at 54.02%, while Institutions and Non-Institutions held 26.50% and 19.47% respectively.
Jubilant Life Sciences, an integrated global Pharmaceutical and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval for Itraconazole Capsules, 100 mg, the generic version of Sporanox of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.
The company has received 8 approvals from the USFDA during the year. As on December 31, 2016, the pharma major had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved.
Jubilant Life Sciences is engaged in manufacturing and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.